United States· US:49502-476_99ba96bb-da73-4082-bb81-c573f6019013
Pretomanid
A pretomanid product containing pretomanid, registered in United States by Viatris Specialty LLC. The same ATC class is registered in 10 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Pretomanid is registered in 10 of 19 countries.
Countries holding a registration under ATC J04AK08 (pretomanid), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Pretomanid · ATC J04AK08
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- PRETOMANID
- Manufacturer
- Viatris Specialty LLC
- Country
- United States (US)
- ATC code
- J04AK08
- ATC class
- Pretomanid
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1149502476261 BOTTLE in 1 CARTON (49502-476-26) / 26 TABLET in 1 BOTTLE
- ndc1149502-476-26
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
20 interactions on record for pretomanid.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pretomanid · interactions on record
20 records
- 9 severe
- 11 moderate
Most severe, free to view
- DexamethasoneH02AB02severe
- DabrafenibL01EC02severe
- LorlatinibL01ED05severe
- DabrafenibL01XE23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pretomanid in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDOVPRELAMylan IRE Healthcare Limited, Dublin
- FinlandDovprelaMylan IRE Healthcare Limited
- FranceDOVPRELA 200 mg, compriméMYLAN IRE HEALTHCARE (IRLANDE)
- United KingdomDovprela 200mg tabletsImported (Italy)
- IrelandDovprela 200 mg tabletsMylan IRE Healthcare Limited
- IcelandDovprelaMylan IRE Healthcare Limited
- NetherlandsDovprela 200 mg tabletMylan IRE Healthcare Limited
- NorwayDovprelaMylan
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Dovprela
- Liechtenstein · Dovprela
- Norway · Dovprela
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/de73d9d6-8324-4062-9d47-deec6d5f450d GET /v1/drugs/de73d9d6-8324-4062-9d47-deec6d5f450d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "200",
"substance": "PRETOMANID",
"productndc": "49502-476",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA212862",
"marketing_category": "NDA"
}See everything about pretomanid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.